{"entity":{"id":"arcagy-gineco","kind":"company","name":"ARCAGY-GINECO","aka":["GINECO","Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens","ARCAGY"],"tldr":"The French gynaecologic cancer trials group that led PAOLA-1, the trial adding olaparib to bevacizumab maintenance in ovarian cancer.","summary":"GINECO was founded in 1993 as France's cooperative group for ovarian, endometrial, cervical and rare gynaecologic cancers, with ARCAGY as its academic sponsor and research organisation. As a founding member of the European ENGOT network and the Gynecologic Cancer InterGroup, it led PAOLA-1/ENGOT-ov25, which showed olaparib plus bevacizumab maintenance improves progression-free and, in HRD-positive disease, overall survival in newly diagnosed ovarian cancer. GINECO also ran the CHIVA and ICON7 contributions, elderly-specific ovarian trials and the rare-tumour TMRG network, and it co-develops immunotherapy trials in endometrial and cervical cancer with the GOG Foundation.","asOf":"2026-09-09","links":[{"label":"ARCAGY-GINECO","url":"https://www.arcagy.org"}],"tags":["cooperative-group"],"related":["olaparib","niraparib"],"cancers":["ovarian","endometrial","cervical"],"sections":[],"technologies":["parp-inhibitor","hrd-testing","antiangiogenic"],"targets":[],"drugs":[],"companies":["gog-foundation","curie-nki-eortc","unicancer"],"institutions":[],"pathways":[],"terms":["hrd"],"trials":["paola-1","gog-0218-icon7"],"people":["sebastien-armanet"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["PAOLA-1 (olaparib plus bevacizumab)","Elderly ovarian cancer trials","ENGOT and GCIG leadership","Rare gynaecologic tumours network"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Paris","country":"FR","companyType":"cooperative-group","website":"https://www.arcagy.org","founded":1993,"investors":[],"funding":[]},"route":"/companies/arcagy-gineco/","neighbours":{"drug":[{"id":"niraparib","kind":"drug","name":"Niraparib","route":"/drugs/niraparib/"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/"}],"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"hrd-testing","kind":"technology","name":"HRD & BRCA testing","route":"/technologies/hrd-testing/"},{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"}],"company":[{"id":"curie-nki-eortc","kind":"company","name":"EORTC","route":"/companies/curie-nki-eortc/"},{"id":"gog-foundation","kind":"company","name":"GOG Foundation","route":"/companies/gog-foundation/"},{"id":"unicancer","kind":"company","name":"UNICANCER","route":"/companies/unicancer/"}],"term":[{"id":"hrd","kind":"term","name":"Homologous recombination deficiency (HRD)","route":"/terms/hrd/"}],"trial":[{"id":"gog-0218-icon7","kind":"trial","name":"GOG-0218 & ICON7 (bevacizumab)","route":"/trials/gog-0218-icon7/"},{"id":"paola-1","kind":"trial","name":"PAOLA-1 / ENGOT-ov25","route":"/trials/paola-1/"},{"id":"senticol-iii","kind":"trial","name":"SENTICOL III","route":"/trials/senticol-iii/"}],"person":[{"id":"isabelle-ray-coquard","kind":"person","name":"Isabelle Ray-Coquard","route":"/people/isabelle-ray-coquard/"},{"id":"sebastien-armanet","kind":"person","name":"Sébastien Armanet","route":"/people/sebastien-armanet/"}],"institution":[{"id":"esgo","kind":"institution","name":"European Society of Gynaecological Oncology","route":"/institutions/esgo/"}]}}